Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Ironwood Pharmaceuticals ( IRWD ) stock is buoyant today, up >15%, despite the CMS announcing the list price of its drug Linzess will be slashed from 2027, from $568 per month, to $136.Edmund Ingham is a biotech co ...